Takeda Pharmaceutical Company Limited

Tadahiro Nambu

Akihiro Ohashi

Kenichi Iwai

Kazunori Yamanaka

Huifeng Niu

Ryo Dairiki

Yuko Ishii

Kentaro Otake

Hyunjin Shin

Erik Michael Koenig

The present disclosure relates to methods useful for determining whether to treat cancer in a patient, and treating cancer in a patient, by administering a therapeutically effective amount of Compound 1 and/or tautomers thereof or a pharmaceutically acceptable salt or hydrate thereof.

Cancer treatment methods based on TP53 mutation status and hypermutation

The present invention relates to a method of predicting the likelihood that a patient will respond therapeutically to a pancreatic cancer treatment comprising the administration of 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one (Compound 1) and/or tautomers thereof or a pharmaceutically acceptable salt or hydrate thereof, comprising the steps of: STEP (1): determining a KRAS gene mutation status of a sample from a patient, and STEP (2): predicting an increased likelihood that the patient will respond therapeutically to the pancreatic cancer treatment if the patient has the presence of KRAS gene mutation(s), and to methods of treating pancreatic cancer.

Method of predicting effects of CDC7 inhibitor

Growing community of inventors

Kanagawa, Japan

Tadahiro Nambu